Maxcyte Inc MXCT

$1.07 -0.02 (-1.83%)

Valuation

Market cap
112,495,000
Revenue TTM
$33,030,000
Net income TTM
$-44,630,000
PE ratio
0.00
Forward PE
—
Profit margin
-135.12%
Debt to equity
0.00

Trading

Volume
228,100
Avg volume
613,514
Day's range
$1.07 – $1.11
Shares out
103,206,000
Stochastic %K
0%
Beta
1.49
Analysts
Strong Sell
Price target
$4.67

Price

Company profile

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GT...

Show more

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Industry
Medical Devices
Sector
Healthcare
Phone
301 944 1700
Website
https://www.maxcyte.com
Address
9713 Key West Avenue, Suite 400, Rockville, United States

Latest news

No headlines yet.

Stocktwits

Ed_Ng Sep 30, 9:18 AM
$MXCT lol
0 replies
Stock_Catcher Aug 13, 2:00 PM
$MXCT 👀
0 replies
burbs88 Aug 13, 1:44 PM
$MXCT What a beautiful bear trap that was.
0 replies
EarningsInsider Aug 12, 9:32 PM
https://www.marketbeat.com/earnings/reports/2026-8-12-maxcyte-inc-stock/ $MXCT MaxCyte Earnings Transcript
0 replies
StocktwitsEarnings Aug 12, 8:21 PM
$MXCT Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.08 up 33.33% YoY • Reported revenue of $7.27M down -14.53% YoY • MaxCyte expects full year 2026 revenue of $30 million to $32 million, consisting of $25 million to $27 million in core revenue and approximately $5 million in SPL Program-related revenue.
0 replies
Hertha Aug 12, 10:45 AM
$MXCT You can extrapolate from VRTX and CRSP: they mentioned good numbers and MXCT is their tollbooth. All this doesn’t take away from the fact: we need to wait until 2028 or later until we know if this is a good investment.
1 replies
HypnoTrader Aug 12, 5:25 AM
$MXCT AI says no.
0 replies
HypnoTrader Aug 12, 2:17 AM
$MXCT up 14% overnight. Earnings are not untill tomorrow afternoon....
1 replies